Needham Maintains Buy on Nurix Therapeutics, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) and keeps the price target at $31.

April 02, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum reaffirms a Buy rating on Nurix Therapeutics with a $31 price target.
The reaffirmation of a Buy rating and a $31 price target by a reputable analyst like Gil Blum from Needham is likely to instill confidence among investors and could positively influence Nurix Therapeutics' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100